Pegfilgastrim after Allogeneic Transplantation - A Alternative to Daily Filgastrim?.

Abstract Long time of aplasie after allogeneic Stem cell- or Bone marrow-transplantation increase the risk of infections complications. Studies showed the positive effect of daily filgastrim to reduce the duration of aplastic time. The use of the Pegfilgastrim promise a simple handle with a single doses after transplantation. Between December 2004 and July 2005 we observed 19 patients with different diseases after SCT or BMT. All patients received a single doses subcutaneous injection of 6 mg pegfilgastrim on day 5 after transplantation. The median leucocytes engraftment was on day 16 after transplantation. The incidence of neutropenic infections was 84 percent with fever unknown origin, 21 percent with catheter induced infections and 10 percent with fungal pneumonia. Side effects of the cytokines had not been observed. The median hospitalisation was 33 days. In compared with the daily doses of Filgastrim 5 mg/kg/day was the duration to leucocytes engraftment and the infections profile similar. The use of the single injection doses of 6 mg pegfilgastrim shows a safe and comfortable profile for patients after allogenic transplantation. Age 17 – 61 years, median 47 years Sex 11 male, 8 female Diseases 8 acute myeloid leukaemia, 1 acute lymphatic leukaemia, 1 chronic myeloid leukaemia, 1 Thalassaemia, 1 non hodgkin lymphoma, 1 osteomyelofibrosis, 5 multiple myeloma, 1 myelodysplastic syndrom Conditioning regime 7 normal conditioning, 12 reduce intensity conditioning Type of transplantation 12 MUD-PBSCT, 5 MMUD-PBSCT, 2 MUD-BMT CD34+ count median 7,9 x 10 6 /kg KG Engraftment of leucocytes median 16 days (10–25 days) Infection disease 16 FUO (84%), 2 fungal-pneumonia (10%), 4 sepsis of catheter (21%) Duration of hospitalisation median 33 days (17 – 47 days)

Download Full-text

Marrow aplasia developing 13 years after HLA-identical sibling allogeneic transplantation for chronic myeloid leukaemia: successful treatment with antithymocyte globulin and peripheral blood stem cell infusion from the original donor

European Journal Of Haematology ◽

10.1111/j.1600-0609.2005.00594.x ◽

2006 ◽

Vol 76 (3) ◽

pp. 258-260 ◽

Cited By ~ 1

Author(s):

D O'Donghaile ◽

P. J. Hayden ◽

S. L. McCarron ◽

E. M. Doyle ◽

M. Lawler ◽

...

Keyword(s):

Stem Cell ◽

Chronic Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Successful Treatment ◽

Peripheral Blood ◽

Antithymocyte Globulin ◽

Peripheral Blood Stem Cell ◽

Allogeneic Transplantation ◽

Blood Stem Cell ◽

Original Donor

Download Full-text

Content of long-term culture-initiating cells, clonogenic progenitors and CD34+ cells in apheresis harvests of normal donors for allogeneic transplantation, and in patients with acute myeloid leukaemia or multiple myeloma

British Journal of Haematology ◽

10.1046/j.1365-2141.1999.01152.x ◽

1999 ◽

Vol 104 (2) ◽

pp. 374-381 ◽

Cited By ~ 4

Author(s):

C. Kasper ◽

W. D. J. Ryder ◽

J. Dürig ◽

K. Nagesh ◽

J. H. Scarffe ◽

...

Keyword(s):

Multiple Myeloma ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Allogeneic Transplantation ◽

Long Term Culture ◽

Cd34 Cells ◽

Acute Myeloid

Download Full-text

Unusual presentation of paediatric anaplastic large cell lymphoma

Bangladesh Journal of Medical Science ◽

10.3329/bjms.v8i4.4711 ◽

1970 ◽

Vol 8 (4) ◽

pp. 135-138

Author(s):

M Irfan ◽

MM Yusri ◽

ABM Farveen

Keyword(s):

Anaplastic Large Cell Lymphoma ◽

Fever Of Unknown Origin ◽

Clinical Presentation ◽

Cell Lymphoma ◽

Unknown Origin ◽

Large Cell ◽

Medical Sciences ◽

Non Hodgkin Lymphoma ◽

Large Cell Lymphoma ◽

Alk Positive

Anaplastic large cell lymphoma (ALCL) is a rare disease. Among childhood non-Hodgkin lymphoma, it constitutes less than 20% of the incidence of all cases. The clinical presentation though is known to be much diversified, most of the patients will present with an enlarged palpable cervical lymphadenopaty. Other reported features include fever of unknown origin, nonspecific pain, cough, shortness of breath, fatigue and malaise. We report a case of ALK-positive ALCL in a patient who presented with submandibular abscess. After defaulted treatment, the mass became fungating externally with everted edge that mimic squamous cell carcinoma. Keywords: ALCL; pediatric; clinical presentation DOI: 10.3329/bjms.v8i4.4711 Bangladesh Journal of Medical Sciences Vol.8(4); October 2009 pp135-138

Download Full-text

Low-Grade Lymphoma

Hematology ◽

10.1182/asheducation-2004.1.203 ◽

2004 ◽

Vol 2004 (1) ◽

pp. 203-220 ◽

Cited By ~ 37

Author(s):

Jane N. Winter ◽

Randy D. Gascoyne ◽

Koen Van Besien

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Treatment Options ◽

B Cell Lymphoma ◽

Allogeneic Transplantation ◽

Low Grade ◽

Non Hodgkin Lymphoma ◽

Treatment Paradigm ◽

Optimal Approach

Abstract Folicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, shows considerable heterogeneity in its clinical behavior, representative of a biology that appears increasingly complex and diverse. As our knowledge of the molecular basis of FL increases, we strive for an integration between the bench and clinic that yields treatments based on our scientific understanding and biomarkers that allow us to prescribe treatment rationally. In Section I, Dr. Randy Gascoyne describes the histologic, cytogenetic and biologic features of FL that underlie its clinical variability. Key aspects of the pathologic diagnosis of FL that have particular relevance to the clinician are highlighted. A proposed model for follicular lymphomagenesis and diffuse large B cell lymphoma transformation has emerged and continues to evolve as the molecular story unfolds. A biologic basis for clinical outcome in FL also appears to be forthcoming. In Section II, Dr. Jane Winter addresses the complex process of selecting among the many treatment options for patients with FL. Previously a simple matter of deciding between oral or intravenous alkylators, clinicians and patients must now struggle to choose among vastly different approaches ranging from “watch and wait” to stem cell transplantation. The introduction of rituximab and radioimmunoconjugates is changing the treatment paradigm, but the optimal approach to integrating these and other new agents remains to be determined. At every decision point, the best approach is always a clinical trial. In Section III, Dr. Koen Van Besien provides a well-documented update on outcomes associated with autologous and allogeneic stem cell transplantation for FL. The results of trials of autologous stem cell transplantation in first remission and recent data supporting a role for graft purging are discussed. Based on the premise that a graft-versus-lymphoma effect is operative in FL, reduced-intensity allogeneic transplantation is the preferred approach in many cases, and recently reported results are summarized. Criteria for patient selection and the optimal role of transplantation in the overall therapeutic plan for the patient with FL are presented.

Download Full-text

57: Outcomes for allogeneic transplantation in imatinib-refractory chronic myeloid leukaemia (CML) are equivalent to outcomes in imatinib-responsive/imatinib-naive CML and can be predicted by the EBMT risk score

Biology of Blood and Marrow Transplantation ◽

10.1016/j.bbmt.2006.12.060 ◽

2007 ◽

Vol 13 (2) ◽

pp. 23-24

Author(s):

S.T. Durrant ◽

S. Stylian ◽

R.J. Western ◽

J.P. Morton ◽

J. Butler ◽

...

Keyword(s):

Chronic Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Risk Score ◽

Allogeneic Transplantation

Download Full-text

t(14;22)(q32;q11) in non-Hodgkin lymphoma and myeloid leukaemia: molecular cytogenetic investigations

British Journal of Haematology ◽

10.1111/j.1365-2141.2005.05688.x ◽

2005 ◽

Vol 130 (6) ◽

pp. 845-851 ◽

Cited By ~ 5

Author(s):

Hege Vangstein Aamot ◽

Merete Bjornslett ◽

Jan Delabie ◽

Sverre Heim

Keyword(s):

Myeloid Leukaemia ◽

Hodgkin Lymphoma ◽

Molecular Cytogenetic ◽

Non Hodgkin Lymphoma

Download Full-text

Prurigo nodularis as index symptom of (non-Hodgkin) lymphoma: ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin

International Journal of Dermatology ◽

10.1111/ijd.12022 ◽

2014 ◽

Vol 54 (4) ◽

pp. 462-464 ◽

Cited By ~ 4

Author(s):

Kathrin Schweda ◽

Michael Hainz ◽

Carmen Loquai ◽

Stephan Grabbe ◽

Joachim Saloga ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Diagnostic Tool ◽

Unknown Origin ◽

Prurigo Nodularis ◽

Non Hodgkin Lymphoma ◽

Dermatological Disorders

Download Full-text

Patients with Fever of Unknown Origin and Splenomegaly: Diagnostic Value of Splenectomy and Preoperative Risk Factors Suggestive of Underlying Lymphomas

Acta Haematologica ◽

10.1159/000473859 ◽

2017 ◽

Vol 137 (4) ◽

pp. 240-246

Author(s):

Lu Zhang ◽

Wei Zhang ◽

Huacong Cai ◽

Xinxin Cao ◽

Miao Chen ◽

...

Keyword(s):

Risk Factors ◽

Lymph Nodes ◽

Hodgkin Lymphoma ◽

Fever Of Unknown Origin ◽

Characteristic Curve ◽

Unknown Origin ◽

Final Diagnosis ◽

Diagnostic Value ◽

Discrimination Power ◽

Non Hodgkin Lymphoma

Background: We reviewed patients with fever of unknown origin (FUO) and splenomegaly and assessed the diagnostic value of splenectomy and measured risk factors suggestive of an underlying lymphoma. Methods: FUO patients (n = 83) who had splenomegaly and underwent splenectomy were enrolled into this retrospective single-center study. Clinical presentations were documented and risk factors suggestive of an underlying lymphoma were tested. Results: Seventy-four patients (89.2%) had a diagnosis of lymphoma or not after splenectomy and follow-up. Of those (55.4%) diagnosed with lymphoma, 29 had B-cell non-Hodgkin lymphoma and 12 had T-cell non-Hodgkin lymphoma. The remaining 33 (44.6%) had diseases other than lymphoma. Using multivariate logistic analysis, the following 3 independent risk factors were found to be related to a final diagnosis of lymphoma: age (continuous) (HR 1.086; 95% CI 1.033-1.141; p = 0.001), massively enlarged spleen (HR 7.797; 95% CI 1.267-47.959; p = 0.027), and enlarged intra-abdominal lymph nodes (HR 63.925; 95% CI 7.962-513.219; p < 0.001). The calibration of the model was satisfactory (p = 0.248 using the Hosmer-Lemeshow test), and the discrimination power was good (area under the receiver operating characteristic curve 0.925; 95% CI 0.863-0.987). Conclusions: Splenectomy is an effective diagnostic procedure for patients with FUO and splenomegaly and lymphoma is a common cause. Older age, a massively enlarged spleen, and enlarged intra-abdominal lymph nodes are risk factors suggesting an underlying lymphoma, and surgery for high-risk patients should be considered.

Download Full-text

Utilization of ‘Rainy Day’ Autologous Peripheral Blood Stem Cells.

Blood ◽

10.1182/blood.v110.11.4913.4913 ◽

2007 ◽

Vol 110 (11) ◽

pp. 4913-4913

Author(s):

Dominic Wall ◽

Alexander Yallouridis ◽

Peter Gambell ◽

Ritchie David ◽

Prince Miles

Keyword(s):

Myeloid Leukaemia ◽

Hodgkin Lymphoma ◽

Peripheral Blood ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Common Disease ◽

High Dose ◽

Peripheral Blood Stem Cells ◽

Non Hodgkin Lymphoma ◽

L 14

Abstract High-Dose myeloablative therapy in conjunction with Autologous Peripheral Blood Stem Cell (APBSC) transplantation is an effective first line treatment in patients with haematological malignancies including Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (NHL). With sufficient resources, APBSC’s can be harvested in patients during remission or consolidation treatment for subsequent transplantation if required (‘Rainy Day’ Collection). We investigated the eventual transplantation of ‘Rainy Day’ collections at our centre to assess the utilization of this strategy. We defined ‘Rainy Day’ collections as those that were not intended to be used as part of initial therapy and in general, patients were not planned to be transplanted within the 12 months following harvest. For collections that were transplanted within 12 months following harvest, ‘Rainy Day’ collections were differentiated based on the utilization intent at time of collection. Any collections infused within 3 months following harvest were excluded from the analysis. Over a 6 year period, we collected APBSC’s from 365 patients with the intent of ‘Rainy Day’ storage. Primary disease indications included NHL (45%, n=166), MM (12%, n=44), Acute Myeloid Leukaemia (AML) (8%, n=29) and Chronic Myeloid Leukaemia (CML) (7%, n=25). To date, 23% (n=84) of these ‘Rainy Day’ collections have been subsequently infused. NHL has been the most common disease requiring Rainy Day collections and has resulted in 41 subsequent transplants (24% utilization) with a median time between collection and infusion of 1.74 years (SD =1.60). Mean days until platelets > 20x109/L=15 (SD=7.0) and days until ANC > 0.5x106/L=10 (SD=1.7). Follicular Non-Hodgkin Lymphoma (fNHL) has accounted for the majority of NHL transplants (37%, 5/15), with 5 of 15 patients exhibiting transformation of fNHL into Diffuse Large B-Cell Lymphoma and an average time between collection and infusion of 2.07 years (SD 2.01). Peripheral T-Cell Lymphoma (T-NHL) has contributed to 15% (n=6/41) of transplanted NHL ‘Rainy Day’ collections with a mean time between collection and infusion being shorter at 1.53 years (SD=0.97). 23% of MM patients (n=44/202) have had APBSC’s collected for potential ‘Rainy Day’ utilization compared with 53% of NHL (n=166/309), 86% of AML (n=29/34) and 100% of CML (25/25). MM has shown to have the highest ‘Rainy Day’ APBSC utilisation with 55% (n=23/44) of patients resulting in transplantation. The average time between collection and infusion has been 2.79 years (SD=1.65) with mean days until platelets > 20x109/L=14 (SD =6.9) and days until ANC > 0.5x106/L=10 (SD=1.7). We conclude that it is clinically feasible and safe to perform ‘Rainy Day’ collections although more stringent criteria would result in a more efficient use of this resource intensive strategy.

Download Full-text